Pregnancy-Safe vs Standard Korean Skincare Formulation: How Korean ODMs Substitute Retinoids, Hydroquinone, and Salicylic Acid (Indie K-Beauty 2026)

By the ALTA MEET editorial team | K-beauty ODM consulting

In the last 18 months, "pregnancy-safe" has gone from a niche positioning request to a column we add to almost every indie K-beauty brief that comes through our consulting practice. Founders are not asking for it because the category is trending in glossy magazines. They are asking because their target customer is a 28- to 42-year-old woman who is either pregnant, planning a pregnancy, nursing, or in a friend group where someone always is, and that customer reads ingredient labels with a different lens than the standard K-beauty consumer.

This piece is the comparison brief we wish every founder had before their first Korean ODM call. It is a side-by-side of how a standard Korean skincare formulation differs from a pregnancy-safe one, what Korean ODMs actually substitute when the restricted active comes out, what the 1,000-MOQ landed cost looks like for each, and how to write the brief so your manufacturing partner does not quietly reintroduce a flagged ingredient under a different INCI synonym.

Almost none of this is in the public Korean ODM literature. Most of what is published is either US dermatology consumer content or generic OEM marketing copy. The substitution map, the cost deltas, the brief language, and the MoCRA claim restrictions all sit in the practice of working a brief across the Pacific.

Why Pregnancy-Safe Is the Fastest-Growing Indie K-Beauty Positioning Request in 2026

Two things changed in the last two years that pushed pregnancy-safe out of niche and into mainstream indie K-beauty positioning.

First, the US dermatology community settled on a tighter consensus list of what to avoid during pregnancy. The American Academy of Dermatology, the InfantRisk Center at Texas Tech, and a growing number of OB-GYN practices now publish nearly identical patient handouts: avoid all retinoids, avoid hydroquinone, limit salicylic acid to under 2 percent and ideally avoid frequent leave-on use, avoid oxybenzone, and use mineral sunscreen (Paula's Choice expert advice; InfantRisk Center overview). The list is no longer contested at the level of mainstream prenatal care, which means a buyer who reads it can apply it consistently across brands.

Second, Korean regulatory positioning around pregnancy-related cosmetic claims tightened. On July 10, 2025, the Korean Ministry of Food and Drug Safety (MFDS) revised the Enforcement Rules of the Cosmetics Act under Prime Ministerial Decree No. 1970, adding a new functional cosmetics category for "products that help reduce the appearance of red stretch marks caused by pregnancy" (CIRS Group MFDS revision summary). This is the first time the MFDS has explicitly opened a pregnancy-adjacent claim pathway, which signals that Korean ODMs and regulators are taking pregnancy-tier formulation seriously enough to give it its own legal lane.

The result is a buyer who knows what she does not want, a regulator who has formally acknowledged the category, and a Korean ODM supply base that has been quietly building substitution playbooks for two years while everyone watched. From a brand-building point of view, that is the textbook conditions for a positioning opportunity. Demand is concrete, supply is ready, and the language to differentiate is not yet crowded.

The Ingredient Restriction List: What Korean ODMs Take Out

Korean ODMs working a pregnancy-safe brief generally pull from a five-bucket restriction list. The buckets are settled enough across US dermatology, EU Cosmetic Regulation positioning, and Korean MFDS functional-cosmetic guidance that any reputable Korean ODM will already have an internal version of this list. Where the lists differ is in how strict each ODM is on each bucket.

The first bucket is retinoids. This includes prescription tretinoin, adapalene (Differin), tazarotene, and all over-the-counter forms: retinol, retinaldehyde (retinal), retinyl palmitate, retinyl acetate, retinyl propionate, and hydroxypinacolone retinoate (HPR or granactive retinoid). The reason is that prescription oral retinoids (isotretinoin) are confirmed teratogens, and the dermatology community treats topical retinoids as a precautionary class restriction (Medical News Today retinol alternatives). The risk of occasional small-area topical use is likely theoretical, but no reputable brand sells a "use sparingly" pregnancy product, so the entire class comes out.

The second bucket is hydroquinone. Hydroquinone has a 30 to 40 percent systemic absorption rate after topical use (InfantRisk Center), which is significantly higher than most cosmetic actives. Both the prescription 4 percent forms and the over-the-counter 2 percent forms are excluded. Korean ODMs almost never use hydroquinone in finished cosmetics anyway because the MFDS treats it as a quasi-drug ingredient, but it does occasionally appear in brightening serum briefs from founders who studied the US market and assumed the active was available. It is not, and even if it were, it would come out for the pregnancy-safe line.

The third bucket is salicylic acid above 2 percent leave-on or in any concentration as a frequent-use exfoliant. The US dermatology consensus is that under 2 percent in a rinse-off cleanser is generally tolerated, but daily leave-on toners, serums, and spot treatments are flagged (NBC News dermatology overview). For an indie K-beauty pregnancy-safe line, the cleaner positioning is to remove salicylic acid from the leave-on portfolio entirely and either keep a low-percentage rinse-off cleanser or replace BHA with a gentler exfoliating active.

The fourth bucket is benzoyl peroxide above 5 percent, and any oxybenzone-containing UV filter. Oxybenzone is restricted because of its endocrine-disruption hazard profile and high systemic absorption; this is one of the easiest substitutions because Korean ODMs already work with a 30-plus approved UV filter list under the KFDA framework, far broader than the US 16-filter list (altameet Korean UV filters comparison).

The fifth bucket, which Korean ODMs tend to treat conservatively even when US dermatology is more permissive, includes phthalates, formaldehyde-releasing preservatives, high-concentration essential oils with terpene aldehydes, and chemical sunscreen filters whose pregnancy safety data is thin. Many Korean ODMs will also pull aluminum chlorohydrate out of any antiperspirant adjacency products, and certain peptides marketed with "neurotoxin-like" activity claims (synthetic botulinum-adjacent peptides) for the same precautionary reason.

The sixth ingredient many founders ask about is bakuchiol, and the answer that Korean ODMs give is more cautious than the US wellness press. Bakuchiol is sometimes marketed as a "pregnancy-safe retinol alternative," but the actual research is thin enough that most clinical dermatologists recommend avoiding it until after delivery and breastfeeding (Truly Beauty bakuchiol pregnancy review). A conservative Korean ODM will flag bakuchiol on a pregnancy brief and ask for the brand's risk position before formulating. If the brand wants the bakuchiol claim, the ODM will usually request that the marketing copy be reviewed by the brand's own counsel rather than carrying the claim themselves.

Side-by-Side Comparison Table: Standard vs Pregnancy-Safe Korean ODM Formulation

The clearest way to see what changes when a Korean ODM takes a standard indie K-beauty brief and rebuilds it as a pregnancy-safe version is to lay the two side by side at the typical four-step routine layer.

Routine LayerStandard Korean Indie FormulationPregnancy-Safe Korean Indie FormulationCleanserSalicylic acid 1.5 percent rinse-off, gentle surfactant blendGlycerin and amino acid surfactant base, no salicylic acid, optional rice ferment for skin-finish polishToner / First treatment essenceNiacinamide 5 percent, betaine salicylate or PHA, panthenol, low-pH adjustedNiacinamide 5 percent, lactic acid under 5 percent (rinse-off only) or PHA gluconolactone in low percentage, panthenol, ceramide complexSerum or ampouleGranactive retinoid (HPR) 0.5 percent, peptide complex, niacinamide 4 percent, low-percentage retinol or retinalAzelaic acid 10 percent, niacinamide 4 percent, ascorbyl glucoside or sodium ascorbyl phosphate, ceramide NP, snail mucin or PDRN if positioning allowsSunscreenKorean chemical filter blend (Tinosorb S, Uvinul A Plus, Iscotrizinol)100 percent mineral zinc oxide 18 to 22 percent OR Korean mineral-leaning hybrid with no oxybenzone, no octinoxate, no octocrylene

The substitutions are not casual swaps. Each one carries an R&D cost, a stability test redesign, and an INCI list rework. The serum row is the highest-cost change because azelaic acid is a non-trivial active to stabilize in a Korean ODM gel base, and the ceramide complex change usually requires reformulating the entire vehicle to keep the texture in line with what indie K-beauty consumers expect.

For founders who want a deeper view of how Korean ODMs price these substitutions inside the quote, the line-by-line cost reading we published earlier this year walks through the same math layer-by-layer (altameet how-to-read-a-Korean-ODM-quote guide).

The Korean ODM Substitution Map: What Goes In When the Restricted Active Comes Out

The substitution map is the single most useful piece of paper a founder can hold in their first pregnancy-safe Korean ODM call. Without it, the back-and-forth on what replaces what burns four to six weeks. With it, the brief locks in two calls.

For retinoids, the standard Korean ODM substitution path is azelaic acid at 10 percent for the cell-turnover and pigmentation work, with niacinamide at 4 to 5 percent as the anti-inflammatory and barrier partner. Azelaic acid has FDA pregnancy category B status, meaning animal studies show no fetal risk but human studies are limited, and it is the only active in this group with a 2025 facial-peel clinical study showing measurable wrinkle and elasticity improvement (a small 28-day study found a 4 percent wrinkle-length reduction, a 15 percent wrinkle-count reduction, and an 11 percent elasticity improvement at 28 days, with the standard caveat that small-sample data needs replication) (Today Show retinol alternative review). Korean ODMs typically pair the azelaic acid with a ceramide complex (ceramide NP, NS, AP, EOS, with phytosphingosine and cholesterol) to keep the barrier intact through the cell-turnover acceleration.

For hydroquinone, the substitution is a tyrosinase-pathway active stack. The default Korean ODM choices are alpha-arbutin 2 percent, niacinamide 5 percent, vitamin C in a stable form (sodium ascorbyl phosphate, ascorbyl glucoside, or 3-O-ethyl ascorbic acid for slightly higher potency without the irritation of ascorbic acid), and tranexamic acid 2 to 5 percent. The substitution stack is actually more sophisticated than hydroquinone in some respects because it works on multiple steps of the pigmentation pathway rather than one, though it takes 8 to 12 weeks to show visible results vs the 4 to 6 weeks of hydroquinone monotherapy. For an indie K-beauty pregnancy-safe brand, the longer timeline becomes a use-direction conversation rather than a formulation problem.

For salicylic acid, the Korean ODM substitution path is PHA (polyhydroxy acids, primarily gluconolactone and lactobionic acid) at 3 to 5 percent for daily leave-on use, plus low-percentage lactic acid in rinse-off cleansers and toners only. PHAs have a larger molecular size than AHAs and BHAs, which makes them more surface-acting and less penetrating. This is the property that lets dermatologists tolerate them during pregnancy where they will not tolerate higher-percentage AHAs.

For benzoyl peroxide, the substitution is azelaic acid 10 percent (which covers both pigmentation and anti-inflammatory blemish work) plus low-percentage zinc PCA or zinc oxide microparticles for the sebum-regulation work. Centella asiatica extracts are usually layered in as the soothing partner.

For oxybenzone and chemical-filter UV blockers, the Korean ODM substitution leans heavily on the broader Korean approved UV filter list. Tinosorb M, Tinosorb S, and Uvinul A Plus are restricted from pregnancy-safe formulation in many ODM playbooks even though their pregnancy hazard data is thin, because the brand-side risk position is usually conservative. The default pregnancy-safe choice is non-nano zinc oxide at 18 to 22 percent for daily wear, or a mineral-hybrid using only the most-studied filters. Korean ODMs are unusually well-positioned for this work because their standard formulation base is non-greasy mineral SPF, unlike the US market where mineral SPF has historically had a "white cast" problem the ODM has not solved.

A Note From Liz

I am Liz, I run ALTA MEET from Manhattan, NYC. The pregnancy-safe brief is one of the briefs that founders most often get wrong on the first ODM call, because they treat it like a marketing checkbox rather than a formulation rebuild. The Korean ODM partner you choose has to have done this work before; if they are figuring it out on your dime, your second sample round will cost you another six weeks and another two thousand dollars. If you want a quick gut-check on whether a particular Korean ODM has the pregnancy-safe substitution depth your brand actually needs, grab 15 minutes free with me and we will pressure-test it together.

1,000-MOQ Cost Map: Standard vs Pregnancy-Safe Landed in the US

The cost delta is not what most founders expect. Pregnancy-safe formulation does not double the cost. It adds a controlled premium that lands inside a familiar indie K-beauty price band, with the premium concentrated in two of the four routine layers and not the others.

Across roughly two dozen indie K-beauty briefs that ALTA MEET has worked in the last 18 months, the 1,000-MOQ landed-in-US cost map for the four-step routine looks approximately like this. The standard formulation column is the typical Korean ODM cost for a private-label or light-custom brief; the pregnancy-safe column is the same brief rebuilt with the substitutions described in the previous section.

Routine LayerStandard Korean ODM (USD landed)Pregnancy-Safe Korean ODM (USD landed)DeltaCleanser, 150 ml$1.80 to $2.60$1.95 to $2.85+8 to 10 percentToner / first treatment essence, 150 ml$2.10 to $3.20$2.30 to $3.50+8 to 10 percentSerum or ampoule, 30 ml$4.50 to $7.20$5.40 to $8.50+18 to 20 percentMineral sunscreen, 50 ml$4.20 to $6.10$4.80 to $7.20+14 to 18 percentFour-step kit total$12.60 to $19.10$14.45 to $22.05+14 to 15 percent overall

The serum and the sunscreen carry almost the entire premium, because those are the layers where the active substitution is the most expensive and the stability redesign is the most involved. The cleanser and the toner premiums are essentially the cost of a slightly more conservative preservative system and a slightly tighter raw-material spec. Founders who want the deeper version of this math (how the unit ex-works price stacks into the landed price after duty, freight, MoCRA-related compliance, and tariff allocation) can read the manufacturing cost guide we wrote on the standard math (altameet Korean skincare manufacturing cost guide).

The premium is real, but it is not the differentiator. The differentiator is that a pregnancy-safe SKU sells through at a meaningfully higher full-price rate than a standard indie K-beauty SKU because the buyer is not comparison-shopping across 200 brands on TikTok. She is shopping within a narrow trust frame and is willing to pay for the trust. In the briefs we have worked, the gross margin on a pregnancy-safe SKU at retail averages 4 to 6 points higher than the corresponding standard SKU at the same retail price point, even after the manufacturing premium.

Regulatory Lines: MoCRA Claims, KFDA Functional Cosmetics, EU CPNP

The regulatory layer is where indie founders most often get into trouble on a pregnancy-safe line, and the trouble is not on the formulation side; it is on the claims side. The US, Korean, and EU regulators all draw the line at the same place but use different vocabulary, and the wrong word on a US Amazon listing can pull the brand into a different regulatory category entirely.

In the US, MoCRA (the Modernization of Cosmetics Regulation Act, signed December 2022, enforced from July 2024) treats cosmetics on a structure-function claim basis. A cosmetic can say "made with pregnancy-friendly ingredients" but it cannot say "safe to use during pregnancy" without crossing into therapeutic-claim territory, which would reclassify the product as a drug requiring FDA pre-market approval. The safe claim language for an indie K-beauty pregnancy-safe brand is "formulated without retinoids, hydroquinone, salicylic acid above 2 percent, and oxybenzone" rather than "safe for pregnancy" or "doctor-approved for use during pregnancy." Our MoCRA registration walkthrough breaks out the structure-function vs therapeutic line in more detail for founders working their first US compliance package (altameet FDA Korean skincare import guide).

In Korea, the MFDS treats the pregnancy claim pathway as a functional cosmetics category. As of July 10, 2025, products that help reduce the appearance of red stretch marks caused by pregnancy are formally a functional cosmetic category requiring MFDS notification under the Standards and Testing Methods of Functional Cosmetics. Any brand that wants to make a stretch-mark or pregnancy-specific efficacy claim in the Korean market itself (relevant only if the brand is selling both into the US and back into Korea) needs to be aware that the same product carries a different regulatory burden on each side of the Pacific.

In the EU, the Cosmetic Regulation (EC) 1223/2009 governs cosmetic safety, and the CPNP (Cosmetic Products Notification Portal) is the pre-market notification system. A pregnancy-safe positioning EU-side does not require additional approval, but the responsible person notification needs to include the safety assessment under Annex I, and the claim "pregnancy-safe" itself falls under the Common Criteria Regulation 655/2013 which requires evidential substantiation. The clean EU-compliant version of the claim is the same as the US-compliant version: ingredient-exclusion-based, not benefit-claim-based.

A founder briefing a Korean ODM on a pregnancy-safe line that is intended for US-only distribution can ignore the KFDA pathway entirely, but should write into the brief that the labeling will follow MoCRA structure-function rules and that the claim language is ingredient-exclusion-based. A founder briefing for US and EU distribution should add the Annex I safety assessment requirement to the launch checklist. A founder briefing for US, EU, and Korea distribution should add the MFDS functional cosmetic notification to the launch checklist and budget 6 to 10 additional weeks for the Korean side.

How to Brief Your Korean ODM for a Pregnancy-Safe Line

Most pregnancy-safe ODM briefs that go sideways do so for the same reason: the founder writes "pregnancy-safe" once at the top of the brief and assumes the ODM will fill in the rest. The ODM then fills in the rest from its house playbook, which may or may not match the brand's risk position, the brand's distribution geography, or the brand's retail buyer expectations.

A clean pregnancy-safe brief should explicitly call out four things. First, the exclusion list. Not "no retinoids," but a concrete list naming the INCI synonyms (retinol, retinyl palmitate, retinyl acetate, retinaldehyde, hydroxypinacolone retinoate, granactive retinoid). If the brand has a position on bakuchiol, name it. If the brand is willing to accept salicylic acid under 2 percent in rinse-off cleansers only, name that exception. The ODM cannot read minds, and a single-line "no retinoids" instruction has produced more than one sample round that came back with hydroxypinacolone retinoate in the serum because the ODM categorized it as "not a true retinoid" under its own taxonomy.

Second, the substitution preference list. Naming what the founder wants in is as important as naming what they want out. If the brand wants azelaic acid 10 percent as the retinoid substitute, name it; if the brand is open to bakuchiol or open to a peptide-led alternative, name those options too. The substitution map in the section above is a good starting point but does not need to be locked at brief time; the ODM will usually suggest the best fit for the texture and stability target.

Third, the claim language sheet. The exact label copy the brand intends to use, in the format the brand intends to use it, with the regulatory category specified per market. The ODM does not write the claim; the brand or the brand's regulatory counsel writes the claim. But the ODM needs to know what the claim will be in order to confirm the formulation supports the claim and that the stability and microbiological testing matches the substantiation requirement.

Fourth, the testing checklist. Standard Korean ODM stability protocol under ICH Q1A(R2) (accelerated 40 degrees C plus or minus 2, 75 percent RH plus or minus 5, six months minimum; real-time 25 degrees C plus or minus 2, 60 percent RH plus or minus 5, twelve months minimum) plus ISO 11930 preservative efficacy testing using the five-organism panel (Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Candida albicans, Aspergillus brasiliensis) at 7, 14, and 28 days plus ISO 17516:2014 microbio limits (1,000 CFU per gram leave-on standard products; 100 CFU per gram eye, pediatric, and mucosal-contact products). For a pregnancy-safe line, ask the ODM to flag the heavy-metals panel (lead, mercury, arsenic, cadmium) per the FDA Hazard Analysis and Risk-Based Preventive Controls position rather than the cheaper alternative panel, because pregnancy-tier consumers test brands on this layer.

Founders who want the upstream version of this brief (the workflow that gets a brand from concept to first ODM call to first sample) can pull from our launch timeline piece (altameet how-to-vet-Korean-ODM pre-PO due diligence).

Reviewed for accuracy by ALTA MEET's formulation consulting team.

Key Takeaways

A pregnancy-safe Korean ODM formulation is a structural rebuild of the standard indie K-beauty brief, not a labeling tweak. The actives change, the preservative system tightens, the SPF profile rebuilds around mineral-leaning options, and the claim language shifts to ingredient-exclusion rather than benefit-claim.

The ingredient restriction list across US dermatology, Korean MFDS, and EU CPNP is broadly converged: retinoids, hydroquinone, salicylic acid above 2 percent leave-on, benzoyl peroxide above 5 percent, oxybenzone, phthalates, formaldehyde-releasing preservatives, and high-terpene essential oils. Bakuchiol is treated cautiously by reputable Korean ODMs because the research is thin.

The Korean ODM substitution map for the restricted actives is settled enough to be predictable: azelaic acid plus niacinamide plus ceramide complex replaces retinoids; alpha-arbutin plus stable vitamin C plus tranexamic acid replaces hydroquinone; PHA replaces salicylic acid as the daily leave-on exfoliating active; mineral zinc oxide replaces oxybenzone and the broader chemical-filter set.

The 1,000-MOQ landed-in-US cost premium for the pregnancy-safe rebuild of a four-step routine is approximately 14 to 15 percent, concentrated in the serum and the sunscreen, with the cleanser and the toner taking only single-digit-percent premiums.

The regulatory line in the US under MoCRA, in Korea under MFDS functional cosmetics, and in the EU under CPNP all converge on the same safe claim format: ingredient-exclusion-based, not benefit-claim-based. A brand making the claim "safe to use during pregnancy" is making a therapeutic claim and would be reclassified as a drug. The compliant claim is "formulated without retinoids, hydroquinone, salicylic acid above 2 percent, and oxybenzone."

The brief that gets a clean first sample round names the exclusion list with INCI synonyms, names the substitution preferences, names the claim language by market, and locks the testing checklist to ICH Q1A(R2) plus ISO 11930 plus ISO 17516:2014 plus a full heavy-metals panel.

FAQ

Is a pregnancy-safe SKU worth the manufacturing premium for a first-time indie K-beauty founder?

For most founders, yes. The premium runs 14 to 15 percent on the typical four-step kit, but the sell-through at full price is meaningfully better because the buyer is shopping in a narrower trust frame. The gross margin on a pregnancy-safe SKU at retail tends to land 4 to 6 points higher than the standard SKU at the same retail price. The exception is a founder whose brand is purely positioned around active-led results (clinical retinoid-tier pigmentation correction, for example); in that case, a pregnancy-safe sub-line under the main brand is usually a stronger move than rebuilding the hero SKU.

Will a Korean ODM let me do a 500-unit pregnancy-safe pilot before committing to 1,000?

Some will, some will not. The Korean ODMs with flexible-MOQ programs (small in-house batches, bridge runs, batch-share arrangements) will typically accept 500 units for a pregnancy-safe pilot but charge a 20 to 35 percent per-unit premium on the bridge run to compensate for the line setup and the testing rework. The 1,000-MOQ number is the cost point where the premium evaporates. Our flexible-MOQ guide walks through the math for sub-1,000 pilots (altameet flexible-MOQ Korean cosmetics guide).

Can my pregnancy-safe brand claim "obstetrician-recommended" or "dermatologist-tested for pregnancy"?

Only with specific evidence. "Obstetrician-recommended" requires named obstetricians who have actually recommended the product, in a documented form that can be produced if the FTC asks. "Dermatologist-tested" is a lower bar but still requires a documented test by a dermatologist on actual product, with results on file. For pregnancy-specific testing claims, the documentation also needs to address that the test was conducted under conditions appropriate for the pregnancy claim. The cleanest path is to avoid the appeal-to-authority claim entirely and let the ingredient-exclusion claim do the work.

How long does the Korean ODM rebuild from a standard indie brief to a pregnancy-safe version take?

Plan on 12 to 16 weeks from confirmed substitution map to second sample sign-off, vs 6 to 10 weeks for a standard indie brief at the same complexity. The extra time is concentrated in the stability rebuild on the serum (azelaic acid is harder to stabilize than the active it replaces in most cases) and in the sunscreen rebuild (mineral-tier SPF testing takes longer than chemical-filter SPF testing under Korean methods). If the brand needs the line in market for a specific Q4 retail window, the brief should be locked by early Q2 of the same year.

Does pregnancy-safe positioning hurt my brand with non-pregnant customers?

In our experience, no, and often the opposite. The ingredient-exclusion claim sheet ("formulated without retinoids, hydroquinone, salicylic acid above 2 percent, and oxybenzone") reads as a clean-formulation signal to a broader sensitive-skin, perimenopause, and post-procedure consumer segment, all of which are growing indie K-beauty audiences. The "pregnancy-safe" name in the brand positioning can be moderated to "for pregnancy and sensitive skin" or "pregnancy-friendly, made for everyone" if the founder is worried about narrowing the audience.

What is the most common Korean ODM red flag on a pregnancy-safe brief?

The substitution of hydroxypinacolone retinoate (HPR, sometimes labeled granactive retinoid) when the brief says "no retinoids." HPR is sometimes treated by less-experienced Korean ODMs as a "next-generation retinol alternative" rather than a retinoid, which it is. Always confirm in writing that the ODM's pregnancy-safe playbook excludes HPR. Same goes for "encapsulated retinol" or "stabilized retinol" framing; encapsulation does not change the regulatory or risk position.

Should I add pregnancy-safe testing to my regular indie K-beauty SKU even if I am not making the claim?

If the founder anticipates a pregnant or nursing customer reading the ingredient list and emailing customer support, then yes, having the cleaner test panel on file is worth the modest additional cost (typically $400 to $700 per SKU on the heavy-metals panel, $150 to $300 per SKU on the additional ISO 11930 stress conditions). The brand does not have to claim pregnancy-safe to have the testing on file; the testing on file is what lets customer support give a confident answer when the question arrives.

Working With ALTA MEET

ALTA MEET is a boutique K-beauty manufacturing consultancy in Manhattan, NYC, working as an outsourced product team for US indie beauty founders building with Korean ODMs. We have worked roughly two dozen indie K-beauty briefs across pregnancy-safe, fragrance-free, sensitive-skin, post-procedure, and standard indie positioning over the last 18 months. If the pregnancy-safe brief on your desk is the one your brand is wrestling with right now, the fastest way to pressure-test it is a short call.

Book your free 15-min K-Beauty manufacturing gut-check with Liz. Fifteen minutes, no pitch, two routing questions that point you at whether Korean ODM fits your project or whether a different manufacturing geography would serve you better.